2023 Targeted Therapies of Lung Cancer Meeting (Poster)-P1.15. Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer by Prior Line of Systemic Therapy and Performance Status

P1.15. Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer by Prior Line of Systemic Therapy and Performance Status

Back to course

Pdf Summary

This study evaluated the efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer who had received prior systemic therapy. Larotrectinib is a first-in-class TRK inhibitor that has been approved for the treatment of TRK fusion cancer. The study included 26 patients with TRK fusion lung cancer, with a median age of 51.5 years. The primary endpoint was the objective response rate (ORR), which was assessed by an independent review committee (IRC). <br /><br />The results showed that larotrectinib demonstrated rapid and durable responses in patients with TRK fusion lung cancer. The IRC-assessed ORR was 83%, and the median duration of response was not reached. The 24-month progression-free survival (PFS) rate was 67%, and the median overall survival (OS) was 40.7 months. These results suggest that larotrectinib could be an effective treatment option for patients with TRK fusion lung cancer, including those with central nervous system (CNS) metastases.<br /><br />In terms of safety, most treatment-related adverse events (TRAEs) reported were Grade 1-2, and there were no treatment discontinuations due to TRAEs. Five patients experienced Grade 3 TRAEs, but these were manageable and did not require treatment discontinuation.<br /><br />Overall, these findings support the use of larotrectinib as a targeted therapy for patients with TRK fusion lung cancer, and suggest that next-generation sequencing fusion panels should be used to identify patients who would benefit from this treatment. Further research is needed to confirm these results and explore the long-term benefits and safety of larotrectinib in this patient population.

Asset Subtitle

Matteo Repetto, Memorial Sloan Kettering Cancer Center, United States

Meta Tag

Speaker Matteo Repetto, Memorial Sloan Kettering Cancer Center, United States

Topic Poster Listing

Keywords

larotrectinib

efficacy

safety

TRK fusion lung cancer

systemic therapy

TRK inhibitor

objective response rate

progression-free survival

overall survival

central nervous system metastases